Role of the microenvironment in hepatocellular carcinoma development and progression

Cancer Treatment Reviews

Volumn 38, Issue 3, 2012, Pages 218-225

  Wu, Sheng Di ^a   Ma, Yu Shui ^a   Fang, Ying ^a   Liu, Li Li ^a   Fu, Da ^a   Shen, Xi Zhong ^a  

^a FUDAN UNIVERSITY   (China)

Author keywords

Anti cancer therapy; ECM; HCC; Hypoxia; Molecular target; Tumor microenvironment

Indexed keywords

ADRENOMEDULLIN; CHEMOKINE; CYCLOOXYGENASE 2; CYTOKINE; GELATINASE A; GELATINASE B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 8; MACROPHAGE ELASTASE; MATRILYSIN; TUMOR SUPPRESSOR PROTEIN; VASCULOTROPIN; WNT PROTEIN;

ANGIOGENESIS; CANCER GROWTH; CANCER INVASION; CELL INTERACTION; CELL PROLIFERATION; CYTOKINE RELEASE; DENDRITIC CELL; ENDOTHELIUM CELL; ENVIRONMENTAL FACTOR; EXTRACELLULAR MATRIX; FIBROBLAST; GENE EXPRESSION; HYPOXIA; LIVER CELL CARCINOMA; LIVER FIBROSIS; METASTASIS; PERICYTE; REVIEW; STELLATE CELL; STEM CELL; STROMA CELL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT;

ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; DENDRITIC CELLS; DISEASE PROGRESSION; EXTRACELLULAR MATRIX; HUMANS; LIVER NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; STROMAL CELLS; TUMOR MICROENVIRONMENT;

EID: 84857652096     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2011.06.010     Document Type: Review

References (121)

1. Jemal A., Siegel R., Ward E., Hao Y., Xu J., Thun M.J. Cancer statistics, 2009. CA Cancer J Clin 2009, 59:225-249.
2. Schrader J., Iredale J.P. The inflammatory microenvironment of HCC - the plot becomes complex. J Hepatol 2011, 54:853-855.
3. De Wever O., Demetter P., Mareel M., Bracke M. Stromal myofibroblasts are drivers of invasive cancer growth. Int J Cancer 2008, 123:2229-2238.
4. Xing F., Saidou J., Watabe K. Cancer associated fibroblasts (CAFs) in tumor microenvironment. Front Biosci 2010, 15:166-179.
5. Amann T., Bataille F., Spruss T., et al. Activated hepatic stellate cells promote tumorigenicity of hepatocellular carcinoma. Cancer Sci 2009, 100:646-653.
6. Xia Y., Chen R., Song Z., et al. Gene expression profiles during activation of cultured rat hepatic stellate cells by tumoral hepatocytes and fetal bovine serum. J Cancer Res Clin Oncol 2010, 136:309-321.
7. Sancho-Bru P., Juez E., Moreno M., et al. Hepatocarcinoma cells stimulate the growth, migration and expression of pro-angiogenic genes in human hepatic stellate cells. Liver Int 2010, 30:31-41.
8. Mantovani A., Sica A., Allavena P., Garlanda C., Locati M. Tumor-associated macrophages and the related myeloid-derived suppressor cells as a paradigm of the diversity of macrophage activation. Hum Immunol 2009, 70:325-330.
9. Redente E.F., Dwyer-Nield L.D., Merrick D.T., et al. Tumor progression stage and anatomical site regulate tumor-associated macrophage and bone marrow-derived monocyte polarization. Am J Pathol 2010, 176:2972-2985.
10. Mantovani A., Sozzani S., Locati M., Allavena P., Sica A. Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002, 23:549-555.
11. Lewis C.E., Pollard J.W. Distinct role of macrophages in different tumor microenvironments. Cancer Res 2006, 66:605-612.
12. Ryschich E., Lizdenis P., Ittrich C., et al. Molecular fingerprinting and autocrine growth regulation of endothelial cells in a murine model of hepatocellular carcinoma. Cancer Res 2006, 66:198-211.
13. Yu Q. The dynamic roles of angiopoietins in tumor angiogenesis. Future Oncol 2005, 1:475-484.
14. Amin D.N., Hida K., Bielenberg D.R., Klagsbrun M. Tumor endothelial cells express epidermal growth factor receptor (EGFR) but not ErbB3 and are responsive to EGF and to EGFR kinase inhibitors. Cancer Res 2006, 66:2173-2180.
15. Rolny C., Nilsson I., Magnusson P., et al. Platelet-derived growth factor receptor-beta promotes early endothelial cell differentiation. Blood 2006, 108:1877-1886.
16. Darland D.C., Massingham L.J., Smith S.R., Piek E., Saint-Geniez M., D'Amore P.A. Pericyte production of cell-associated VEGF is differentiation-dependent and is associated with endothelial survival. Dev Biol 2003, 264:275-288.
17. Kale S., Hanai J., Chan B., et al. Microarray analysis of in vitro pericyte differentiation reveals an angiogenic program of gene expression. FASEB J 2005, 19:270-271.
18. Hall A.P. Review of the pericyte during angiogenesis and its role in cancer and diabetic retinopathy. Toxicol Pathol 2006, 34:763-775.
19. Lin A., Schildknecht A., Nguyen L.T., Ohashi P.S. Dendritic cells integrate signals from the tumor microenvironment to modulate immunity and tumor growth. Immunol Lett 2010, 127:77-84.
20. Matthews V.B., Yeoh G.C. Liver stem cells. IUBMB Life 2005, 57:549-553.
21. Aquino J.B., Bolontrade M.F., Garcia M.G., Podhajcer O.L., Mazzolini G. Mesenchymal stem cells as therapeutic tools and gene carriers in liver fibrosis and hepatocellular carcinoma. Gene Ther 2010, 17:692-708.
22. Ooi L.P., Crawford D.H., Gotley D.C., et al. Evidence that " myofibroblast-like" cells are the cellular source of capsular collagen in hepatocellular carcinoma. J Hepatol 1997, 26:798-807.
23. Faouzi S., Le B.B., Neaud V., et al. Myofibroblasts are responsible for collagen synthesis in the stroma of human hepatocellular carcinoma: an in vivo and in vitro study. J Hepatol 1999, 30:275-284.
24. Miner J.H. Laminins and their roles in mammals. Microsc Res Tech 2008, 71:349-356.
25. Silva R., D'Amico G., Hodivala-Dilke K.M., Reynolds L.E. Integrins: the keys to unlocking angiogenesis. Arterioscler Thromb Vasc Biol 2008, 28:1703-1713.
26. Kim Y., Lin Q., Glazer P.M., Yun Z. Hypoxic tumor microenvironment and cancer cell differentiation. Curr Mol Med 2009, 9:425-434.
27. Lunt S.J., Chaudary N., Hill R.P. The tumor microenvironment and metastatic disease. Clin Exp Metastasis 2009, 26:19-34.
28. Guirouilh J., Castroviejo M., Balabaud C., Desmouliere A., Rosenbaum J. Hepatocarcinoma cells stimulate hepatocyte growth factor secretion in human liver myofibroblasts. Int J Oncol 2000, 17:777-781.
29. Faouzi S., Lepreux S., Bedin C., et al. Activation of cultured rat hepatic stellate cells by tumoral hepatocytes. Lab Invest 1999, 79:485-493.
30. Neaud V., Faouzi S., Guirouilh J., et al. Human hepatic myofibroblasts increase invasiveness of hepatocellular carcinoma cells: evidence for a role of hepatocyte growth factor. Hepatology 1997, 26:1458-1466.
31. Lewis C., Murdoch C. Macrophage responses to hypoxia: implications for tumor progression and anti-cancer therapies. Am J Pathol 2005, 167:627-635.
32. Mikula M., Proell V., Fischer A.N., Mikulits W. Activated hepatic stellate cells induce tumor progression of neoplastic hepatocytes in a TGF-beta dependent fashion. J Cell Physiol 2006, 209:560-567.
33. Theret N., Musso O., Turlin B., et al. Increased extracellular matrix remodeling is associated with tumor progression in human hepatocellular carcinomas. Hepatology 2001, 34:82-88.
34. Kuperwasser C., Chavarria T., Wu M., et al. Reconstruction of functionally normal and malignant human breast tissues in mice. Proc Natl Acad Sci USA 2004, 101:4966-4971.
35. Grum-Schwensen B., Klingelhofer J., Berg C.H., et al. Suppression of tumor development and metastasis formation in mice lacking the S100A4(mts1) gene. Cancer Res 2005, 65:3772-3780.
36. Goh P.P., Sze D.M., Roufogalis B.D. Molecular and cellular regulators of cancer angiogenesis. Curr Cancer Drug Targets 2007, 7:743-758.
37. Orimo A., Gupta P.B., Sgroi D.C., et al. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell 2005, 121:335-348.
38. Mueller L., Goumas F.A., Affeldt M., et al. Stromal fibroblasts in colorectal liver metastases originate from resident fibroblasts and generate an inflammatory microenvironment. Am J Pathol 2007, 171:1608-1618.
39. Lewis C.E., Pollard J.W. Distinct role of macrophages in different tumor microenvironments. Cancer Res 2006, 66:605-612.
40. Nakagawa H., Liyanarachchi S., Davuluri R.V., et al. Role of cancer-associated stromal fibroblasts in metastatic colon cancer to the liver and their expression profiles. Oncogene 2004, 23:7366-7377.
41. Infante J.R., Matsubayashi H., Sato N., et al. Peritumoral fibroblast SPARC expression and patient outcome with resectable pancreatic adenocarcinoma. J Clin Oncol 2007, 25:319-325.
42. Aravalli R.N., Steer C.J., Sahin M.B., Cressman E.N. Stem cell origins and animal models of hepatocellular carcinoma. Dig Dis Sci 2010, 55:1241-1250.
43. Bergamini C., Sgarra C., Trerotoli P., et al. Laminin-5 stimulates hepatocellular carcinoma growth through a different function of alpha6beta4 and alpha3beta1 integrins. Hepatology 2007, 46:1801-1809.
44. Kikkawa Y., Sudo R., Kon J., et al. Laminin alpha 5 mediates ectopic adhesion of hepatocellular carcinoma through integrins and/or Lutheran/basal cell adhesion molecule. Exp Cell Res 2008, 314:2579-2590.
45. Giannelli G., Bergamini C., Fransvea E., Sgarra C., Antonaci S. Laminin-5 with transforming growth factor-beta1 induces epithelial to mesenchymal transition in hepatocellular carcinoma. Gastroenterology 2005, 129:1375-1383.
46. Maegdefrau U., Amann T., Winklmeier A., et al. Bone morphogenetic protein 4 is induced in hepatocellular carcinoma by hypoxia and promotes tumour progression. J Pathol 2009, 218:520-529.
47. Song J., Qu Z., Guo X., et al. Hypoxia-induced autophagy contributes to the chemoresistance of hepatocellular carcinoma cells. Autophagy 2009, 5:1131-1144.
48. Yang Z.F., Poon R.T. Vascular changes in hepatocellular carcinoma. Anat Rec (Hoboken) 2008, 291:721-734.
49. Lindahl P., Johansson B.R., Leveen P., Betsholtz C. Pericyte loss and microaneurysm formation in PDGF-B-deficient mice. Science 1997, 277:242-245.
50. Hirschi K.K., D'Amore P.A. Control of angiogenesis by the pericyte: molecular mechanisms and significance. EXS 1997, 79:419-428.
51. Benjamin L.E., Hemo I., Keshet E. A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development 1998, 125:1591-1598.
52. Kale S., Hanai J., Chan B., et al. Microarray analysis of in vitro pericyte differentiation reveals an angiogenic program of gene expression. FASEB J 2005, 19:270-271.
53. Yu D., Sun X., Qiu Y., et al. Identification and clinical significance of mobilized endothelial progenitor cells in tumor vasculogenesis of hepatocellular carcinoma. Clin Cancer Res 2007, 13:3814-3824.
54. Sunderkotter C., Goebeler M., Schulze-Osthoff K., Bhardwaj R., Sorg C. Macrophage-derived angiogenesis factors. Pharmacol Ther 1991, 51:195-216.
55. Lewis C.E., Leek R., Harris A., McGee J.O. Cytokine regulation of angiogenesis in breast cancer: the role of tumor-associated macrophages. J Leukoc Biol 1995, 57:747-751.
56. Murdoch C., Giannoudis A., Lewis C.E. Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. Blood 2004, 104:2224-2234.
57. Itano N., Zhuo L., Kimata K. Impact of the hyaluronan-rich tumor microenvironment on cancer initiation and progression. Cancer Sci 2008, 99:1720-1725.
58. Kim S., Bell K., Mousa S.A., Varner J.A. Regulation of angiogenesis in vivo by ligation of integrin alpha5beta1 with the central cell-binding domain of fibronectin. Am J Pathol 2000, 156:1345-1362.
59. Gaggioli C., Hooper S., Hidalgo-Carcedo C., et al. Fibroblast-led collective invasion of carcinoma cells with differing roles for RhoGTPases in leading and following cells. Nat Cell Biol 2007, 9:1392-1400.
60. Hall A.P. Review of the pericyte during angiogenesis and its role in cancer and diabetic retinopathy. Toxicol Pathol 2006, 34:763-775.
61. Song G., Ohashi T., Sakamoto N., Sato M. Adhesive force of human hepatoma HepG2 cells to endothelial cells and expression of E-selectin. Mol Cell Biomech 2006, 3:61-68.
62. Wu X.Z., Xie G.R., Chen D. Hypoxia and hepatocellular carcinoma: The therapeutic target for hepatocellular carcinoma. J Gastroenterol Hepatol 2007, 22:1178-1182.
63. Liu L., Zhu X.D., Wang W.Q., et al. Activation of beta-catenin by hypoxia in hepatocellular carcinoma contributes to enhanced metastatic potential and poor prognosis. Clin Cancer Res 2010, 16:2740-2750.
64. Hamaguchi T., Iizuka N., Tsunedomi R., et al. Glycolysis module activated by hypoxia-inducible factor 1alpha is related to the aggressive phenotype of hepatocellular carcinoma. Int J Oncol 2008, 33:725-731.
65. Rofstad E.K., Mathiesen B., Kindem K., Galappathi K. Acidic extracellular pH promotes experimental metastasis of human melanoma cells in athymic nude mice. Cancer Res 2006, 66:6699-6707.
66. Pietras K., Pahler J., Bergers G., Hanahan D. Functions of paracrine PDGF signaling in the proangiogenic tumor stroma revealed by pharmacological targeting. PLoS Med 2008, 5:e19.
67. Zhu X.D., Zhang J.B., Zhuang P.Y., et al. High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma. J Clin Oncol 2008, 26:2707-2716.
68. Benetti A., Berenzi A., Gambarotti M., et al. Transforming growth factor-beta1 and CD105 promote the migration of hepatocellular carcinoma-derived endothelium. Cancer Res 2008, 68:8626-8634.
69. Hu L., Sham J.S., Xie D., et al. Up-regulation of fibroblast growth factor 3 is associated with tumor metastasis and recurrence in human hepatocellular carcinoma. Cancer Lett 2007, 252:36-42.
70. Ho H.K., Pok S., Streit S., et al. Fibroblast growth factor receptor 4 regulates proliferation, anti-apoptosis and alpha-fetoprotein secretion during hepatocellular carcinoma progression and represents a potential target for therapeutic intervention. J Hepatol 2009, 50:118-127.
71. Amann T., Bataille F., Spruss T., et al. Reduced expression of fibroblast growth factor receptor 2IIIb in hepatocellular carcinoma induces a more aggressive growth. Am J Pathol 2010, 176:1433-1442.
72. Takai H., Kato A., Kato C., et al. The expression profile of glypican-3 and its relation to macrophage population in human hepatocellular carcinoma. Liver Int 2009, 29:1056-1064.
73. Zeng Z., Yao W., Xu X., et al. Hepatocellular carcinoma cells deteriorate the biophysical properties of dendritic cells. Cell Biochem Biophys 2009, 55:33-43.
74. Farren M.R., Carlson L.M., Lee K.P. Tumor-mediated inhibition of dendritic cell differentiation is mediated by down regulation of protein kinase C beta II expression. Immunol Res 2010, 46:165-176.
75. Li L., Li S.P., Min J., Zheng L. Hepatoma cells inhibit the differentiation and maturation of dendritic cells and increase the production of regulatory T cells. Immunol Lett 2007, 114:38-45.
76. Bennaceur K., Chapman J.A., Touraine J.L., Portoukalian J. Immunosuppressive networks in the tumour environment and their effect in dendritic cells. Biochim Biophys Acta 2009, 1795:16-24.
77. Tang T.J., Vukosavljevic D., Janssen H.L., et al. Aberrant composition of the dendritic cell population in hepatic lymph nodes of patients with hepatocellular carcinoma. Hum Pathol 2006, 37:332-338.
78. Yu H., Kortylewski M., Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 2007, 7:41-51.
79. Chen Y.X., Man K., Ling G.S., et al. A crucial role for dendritic cell (DC) IL-10 in inhibiting successful DC-based immunotherapy: superior antitumor immunity against hepatocellular carcinoma evoked by DC devoid of IL-10. J Immunol 2007, 179:6009-6015.
80. Qiao L., Zhao T.J., Wang F.Z., Shan C.L., Ye L.H., Zhang X.D. NF-kappaB downregulation may be involved the depression of tumor cell proliferation mediated by human mesenchymal stem cells. Acta Pharmacol Sin 2008, 29:333-340.
81. Qiao L., Xu Z., Zhao T., et al. Suppression of tumorigenesis by human mesenchymal stem cells in a hepatoma model. Cell Res 2008, 18:500-507.
82. Mundel T.M., Kalluri R. Type IV collagen-derived angiogenesis inhibitors. Microvasc Res 2007, 74:85-89.
83. Hedlund E.M., Hosaka K., Zhong Z., Cao R., Cao Y. Malignant cell-derived PlGF promotes normalization and remodeling of the tumor vasculature. Proc Natl Acad Sci USA 2009, 106:17505-17510.
84. Ju M.J., Qiu S.J., Fan J., et al. Peritumoral activated hepatic stellate cells predict poor clinical outcome in hepatocellular carcinoma after curative resection. Am J Clin Pathol 2009, 131:498-510.
85. Ding T., Xu J., Wang F., et al. High tumor-infiltrating macrophage density predicts poor prognosis in patients with primary hepatocellular carcinoma after resection. Hum Pathol 2009, 40:381-389.
86. Cai X.Y., Gao Q., Qiu S.J., et al. Dendritic cell infiltration and prognosis of human hepatocellular carcinoma. J Cancer Res Clin Oncol 2006, 132:293-301.
87. Ho J.W., Pang R.W., Lau C., et al. Significance of circulating endothelial progenitor cells in hepatocellular carcinoma. Hepatology 2006, 44:836-843.
88. Welen K., Jennbacken K., Tesan T., Damber J.E. Pericyte coverage decreases invasion of tumour cells into blood vessels in prostate cancer xenografts. Prostate Cancer Prostatic Dis 2009, 12:41-46.
89. Yonenaga Y., Mori A., Onodera H., et al. Absence of smooth muscle actin-positive pericyte coverage of tumor vessels correlates with hematogenous metastasis and prognosis of colorectal cancer patients. Oncology 2005, 69:159-166.
90. O'Keeffe M.B., Devlin A.H., Burns A.J., et al. Investigation of pericytes, hypoxia, and vascularity in bladder tumors: association with clinical outcomes. Oncol Res 2008, 17:93-101.
91. Jia J.B., Wang W.Q., Sun H.C., et al. High expression of macrophage colony-stimulating factor-1 receptor in peritumoral liver tissue is associated with poor outcome in hepatocellular carcinoma after curative resection. Oncologist 2010, 15:732-743.
92. Xie H., Song J., Liu K., et al. The expression of hypoxia-inducible factor-1alpha in hepatitis B virus-related hepatocellular carcinoma: correlation with patients' prognosis and hepatitis B virus X protein. Dig Dis Sci 2008, 53:3225-3233.
93. Simon F., Bockhorn M., Praha C., et al. Deregulation of HIF1-alpha and hypoxia-regulated pathways in hepatocellular carcinoma and corresponding non-malignant liver tissue-influence of a modulated host stroma on the prognosis of HCC. Langenbecks Arch Surg 2010, 395:395-405.
94. Park S.C., Yoon J.H., Lee J.H., et al. Hypoxia-inducible adrenomedullin accelerates hepatocellular carcinoma cell growth. Cancer Lett 2008, 271:314-322.
95. Hu T.H., Huang C.C., Wu C.L., et al. Increased endostatin/collagen XVIII expression correlates with elevated VEGF level and poor prognosis in hepatocellular carcinoma. Mod Pathol 2005, 18:663-672.
96. Zhang Y., Qu Z.H., Cui M., et al. Combined endostatin and TRAIL gene transfer suppresses human hepatocellular carcinoma growth and angiogenesis in nude mice. Cancer Biol Ther 2009, 8:466-473.
97. Liu Z., Wang J., Yin P., et al. RGD-FasL induces apoptosis in hepatocellular carcinoma. Cell Mol Immunol 2009, 6:285-293.
98. Finn R.S., Zhu A.X. Targeting angiogenesis in hepatocellular carcinoma: focus on VEGF and bevacizumab. Expert Rev Anticancer Ther 2009, 9:503-509.
99. Hsu C.H., Yang T.S., Hsu C., et al. Efficacy and tolerability of bevacizumab plus capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma. Br J Cancer 2010, 102:981-986.
100. Wang W., Wu F., Fang F., Tao Y., Yang L. RhoC is essential for angiogenesis induced by hepatocellular carcinoma cells via regulation of endothelial cell organization. Cancer Sci 2008, 99:2012-2018.
101. Bergers G., Song S., Meyer-Morse N., Bergsland E., Hanahan D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J Clin Invest 2003, 111:1287-1295.
102. Erber R., Thurnher A., Katsen A.D., et al. Combined inhibition of VEGF and PDGF signaling enforces tumor vessel regression by interfering with pericyte-mediated endothelial cell survival mechanisms. FASEB J 2004, 18:338-340.
103. Mazzocca A., Fransvea E., Dituri F., Lupo L., Antonaci S., Giannelli G. Down-regulation of connective tissue growth factor by inhibition of transforming growth factor beta blocks the tumor-stroma cross-talk and tumor progression in hepatocellular carcinoma. Hepatology 2010, 51:523-534.
104. Tsuchiyama T., Nakamoto Y., Sakai Y., Mukaida N., Kaneko S. Optimal amount of monocyte chemoattractant protein-1 enhances antitumor effects of suicide gene therapy against hepatocellular carcinoma by M1 macrophage activation. Cancer Sci 2008, 99:2075-2082.
105. Sun K., Wang L., Zhang Y. Dendritic cell as therapeutic vaccines against tumors and its role in therapy for hepatocellular carcinoma. Cell Mol Immunol 2006, 3:197-203.
106. Nakamoto Y., Mizukoshi E., Tsuji H., et al. Combined therapy of transcatheter hepatic arterial embolization with intratumoral dendritic cell infusion for hepatocellular carcinoma: clinical safety. Clin Exp Immunol 2007, 147:296-305.
107. Mizukoshi E., Nakamoto Y., Arai K., et al. Enhancement of tumor-specific T-cell responses by transcatheter arterial embolization with dendritic cell infusion for hepatocellular carcinoma. Int J Cancer 2010, 126:2164-2174.
108. Koos D., Josephs S.F., Alexandrescu D.T., et al. Tumor vaccines in 2010: need for integration. Cell Immunol 2010, 263:138-147.
109. Gao Y., Yao A., Zhang W., et al. Human mesenchymal stem cells overexpressing pigment epithelium-derived factor inhibit hepatocellular carcinoma in nude mice. Oncogene 2010, 29:2784-2794.
110. Kaspar M., Zardi L., Neri D. Fibronectin as target for tumor therapy. Int J Cancer 2006, 118:1331-1339.
111. WeiXing C., Tiantian H., Qun N., Chaohui Y., Ping X. Inhibitory effect of hypoxia inducible factor-1 antisense oligonucleotide on growth of human hepatocellular carcinoma cells. Med Oncol 2008, 25:88-92.
112. Liu F., Wang P., Jiang X., et al. Antisense hypoxia-inducible factor 1alpha gene therapy enhances the therapeutic efficacy of doxorubicin to combat hepatocellular carcinoma. Cancer Sci 2008, 99:2055-2061.
113. Lapidot T., Sirard C., Vormoor J., et al. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature 1994, 367:645-648.
114. Bonnet D., Dick J.E. Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat Med 1997, 3:730-737.
115. Visvader J.E., Lindeman G.J. Cancer stem cells in solid tumours: accumulating evidence and unresolved questions. Nat Rev Cancer 2008, 8:755-768.
116. Calabrese C., Poppleton H., Kocak M., et al. A perivascular niche for brain tumor stem cells. Cancer Cell 2007, 11:69-82.
117. Riquelme P.A., Drapeau E., Doetsch F. Brain micro-ecologies: neural stem cell niches in the adult mammalian brain. Philos Trans R Soc Lond B Biol Sci 2008, 363:123-137.
118. Boccaccio C., Sabatino G., Medico E., et al. The MET oncogene drives a genetic programme linking cancer to haemostasis. Nature 2005, 434:396-400.
119. Kaplan R.N., Riba R.D., Zacharoulis S., et al. VEGFR1-positive haematopoietic bone marrow progenitors initiate the pre-metastatic niche. Nature 2005, 438:820-827.
120. Borovski T., De Sousa E., Melo F., Vermeulen L., Medema J.P. Cancer stem cell niche: the place to be. Cancer Res 2011, 71:634-639.
121. Hanna E., Quick J., Libutti S.K. The tumour microenvironment: a novel target for cancer therapy. Oral Dis 2009, 15:8-17.